vimarsana.com

Page 10 - அங்கீகாரம் பெற்றது மிகுதி கட்டணம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

National Center for School Evaluation and Excellence signs accreditation agreement with Ma arif

National Center for School Evaluation and Excellence signs accreditation agreement with Ma’arif April 05, 2021 Saudi Gazette report RIYADH On behalf of the Education and Training Evaluation Commission (ETEC), the National Center for School Evaluation and Excellence (Tamayyuz), signed a cooperation agreement with the first foreign education company, Ma’arif for Education and Training, one of the largest private school owners and operators in Saudi Arabia to start implementing school evaluation and accreditation processes for the year 2021. The agreement was signed in the presence of the head of ETEC Hussam Bin Abdel Wahab Zaman and the undersecretary at the Ministry of Investment Mohammed Bin Saleh Al-Wakeel at the ETEC headquarters here.

Texas launches We Hire Ability employer recognition program | News

From Staff Reports 5 hrs ago The Texas Workforce Commission is launching the “We Hire Ability” employer recognition program to celebrate and highlight Texas employers for their commitment to hiring individuals with disabilities and recognizing employers’ important role in helping to ensure a diverse and inclusive Texas workforce. In 2018, an estimated 9.7% of working-age Texans ages 21 to 64, or 1.5 million individuals in Texas reported one or more disabilities. Yet the employment rates among these working-age Texans with a disability is 40.8% while the employment rates of their non-disabled peers are significantly higher at 78.8%. In 2020, the Bureau of Labor Statistics reported that 29.1% of individuals with disabilities ages 16 to 64 were employed, as compared to 70% of individuals ages 16 to 64 without a disability.

Texas launches We Hire Ability employer recognition program | Texas

From Staff Reports 9 hrs ago The Texas Workforce Commission is launching the “We Hire Ability” employer recognition program to celebrate and highlight Texas employers for their commitment to hiring individuals with disabilities and recognizing employers’ important role in helping to ensure a diverse and inclusive Texas workforce. In 2018, an estimated 9.7% of working-age Texans ages 21 to 64, or 1.5 million individuals in Texas reported one or more disabilities. Yet the employment rates among these working-age Texans with a disability is 40.8% while the employment rates of their non-disabled peers are significantly higher at 78.8%. In 2020, the Bureau of Labor Statistics reported that 29.1% of individuals with disabilities ages 16 to 64 were employed, as compared to 70% of individuals ages 16 to 64 without a disability.

Welcome To IANS Live - INTERNATIONAL - Inoculating kids next big ethical debate for UK govt

Photo Credit: IANS IANSLive London, April 1 (IANS) For the UK government, vaccination of children will be the next big ethical debate as the country seeks to recover from the Covid-19 pandemic, local media reported. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 01-April-2021

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope responses. CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and new emerging SARS-CoV-2 variants. CoVepiT, as second-generation vaccine, potentially provides long-term cellular immunity with memory T cells. Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the Belgian Federal Agency for Medicines and Health Products ( Agence Fédérale des Médicaments et des Produits de Santé AFMPS) and the Belgian Ethics Committee approved the Phase 1 trial evaluating its COVID-19 vaccine, named CoVepiT, on 48 healthy volunteers. First subjects are expected to be enrolled shortly.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.